تأثير علاج القلس المعدي المريئي عند مرضى الربو
Abstract
شملت الدراسة 45 مريضاً ربوياً قبلوا في قسم الأطفال في مشفى الأسد الجامعي (اللاذقية) خلال عام واحد (2007-2008). تم تقييم الربو على مدى 3أشهر قبل وبعد علاج القلس, بلغ عدد المرضى الذين لديهم دليل للإصابة بالقلس مثبت بالتنظير الهضمي العلوي25 مريضاً ( 56%) وخضع جميعهم لعلاج القلس. بينما كان التنظير طبيعياً عند 20 مريضاً خضع 10 منهم لعلاج تجريبي للقلس بينما بقي الـ 10 الآخرون كعينة شاهد.
جميع المرضى المصابين بالقلس أبدوا نقصاً واضحاً في استخدام الأدوية الربوية بعد علاج القلس وأوقفواالعلاج بمضاد اللوكوترين بنسبة 100%(P<0,05). أظهر3 مرضى 30)%) غير مصابين بالقلس
وخضعوا لعلاج القلس هذا النقص وأوقف5 مرضى(50%) مضاد اللوكوترين. ولكن لم يبد أي مريض غير مصاب بالقلس ولم يخضع لعلاج تجريبي للقلس أي نقص هام في أدوية الربو وأوقف مريض واحد (10%) مضاد اللوكوترين(P=0,05).
أي أن علاج القلس المعدي المريئي عند مرضى الربو المصابين بالقلس فعال في إنقاص الأدوية الربوية.
The aim of this study was to evaluate the effect of anti GER treatment in asthmatic patients with GER. Asthma outcome was evaluated in 45 asthmatic patients 3 months before and after anti-GER treatment; they were hospitalized for one year (2007-2008) in the Pediatrics Department at AL-ASSAD University Hospital in Latakia. 25 patients (56%) with endoscopic evidence of GER underwent anti GER treatment. 20 patients had normal endoscopy; 10 of them underwent empirical anti-GER treatment, and the others were a control group. The results showed that all patients with GER had a significant reduction in asthmatic medication after anti-GER treatment and stopped antileukotrien100% (P < 0.05). 3 patients (30%) without GER but treated with anti GER treatment showed reduction, and 5 patients (50%) stopped antileukotrien; none of the control group showed any significant reduction in asthma medications, but one patient (10%) stopped anti leukotrien (P=0.05). To conclude, anti GER treatment in asthmatic patients with GER was effective in reducing asthma medication.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.